INTRODUCTION
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death globally [1] , and more than two thirds of patients when diagnosed with unresectable disease [2] . The 5-year overall survival rate of patients with advanced gastric cancer approximately 25% [3] . Currently, platinumbased chemotherapy regimen is the standout chemotherapy frequently used for advanced gastric cancer [4, 5] , and median overall survival and progression free survival was significantly longer in cisplatincontaining combination therapy compared to noncisplatin containing regimens [6, 7] . However, cisplatinbased chemotherapeutic agents are often limited in chemotherapy due to drug resistance [8, 9] . Cisplatin resistance of gastric cancer is multifactorial, accumulating evidence have suggested that the aberrant expression of proteins which associated with decreased cellular accumulation, increased DNA repair capacity, increased drug inactivation [10] play important role in the acquisition of cisplatin resistance. Previous researches have shown that abnormal expression of copper transporter 1 (CTR1) and MRP2 lead to cisplatin resistance by reducing the concentration of cisplatin in cells [11] [12] [13] . Moreover, the upregulation of excision repair cross complementing 1 (ERCC1) [14] , X-ray repair cross complementing 1 (XRCC1) [15] and breast cancer 1 (BRCA1) [16] have
shown to be involved in cisplatin resistance by removal of Pt-DNA adducts [17, 18] . Other studies have shown that downregulation of the human epidermal growth factor receptor II (ErbB2) can significantly enhanced the apoptosis-inducing effects of cisplatin in gastric cancer [19, 20] . The mechanisms of cisplatin resistance are quite complex and have not been fully revealed till now, so investigation of the molecular mechanisms and biomarkers is urgently needed. This study aims to analyze mRNA expression profiles in SGC7901/DDP cells to explore more chemotherapeutic molecular targets and to guide appropriate chemotherapy for gastric cancer with cisplatin resistance.
MATERIALS AND METHODS

Cell lines and culture
The human cisplatin-resistant gastric cancer cell line SGC7901/DDP and its parental cells SGC7901 were purchased from KeyGEN Biotechnology Company (Nanjing, Jiangsu, China). Cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, United States) containing 10% fetal calf serum (Gibco, NY, United States) supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were cultured in a humidified atmosphere with 5% CO2 at 37 ℃. Cisplatin (Sigma, CA, United States) with final concentration of 800 ng/mL was added to the culture media for SGC7901/DDP cells to maintain the cisplatin-resistant phenotype.
MTT method assay for SGC7901/DDP and SGC7901 cells viability
SGC7901/DDP and SGC7901 cells were suspended at a density of 1 × 10 5 cells/mL and planted into 96-well culture plate. After 24 hours, the cells were treated with freshly prepared DDP. The final concentrations were 133.34 μmol /L, 66.67 μmol/L, 6.67 μmol/L, 0.67 μmol/L and 0.067 μmol/L, because the human peak plasma concentration for DDP has been reported as 6 .67 μmol/L [21] . Cell viability was examined after 48 h and was determined by adding 20 μL MTT (5 mg/mL) to each well and incubated for a further 4 h. The resulting formazan crystal was dissolved by addition of 150 μL dimethyl sulfoxide (DMSO) (sigma, Germany) each well, and then plates were shaken for 10 minutes. The absorbance at 490 nm was measured by spectrophotometer (ELx 800; BioTek; Winooski, VT, United States). The inhibition of growth (IC50) for DDP was calculated by the cells relative viability. Each experiment was performed in triplicate.
Total RNA extraction and mRNA microarray
Cells were harvested when they had grown to 80%-90% confluency and were still in logarithmic phase. Total RNA was extracted from the three matched pairs of SGC7901/DDP and SGC7901 cells using TRIzol reagent (Invitrogen, Carlsbad, CA, United States) according to the manufacturer's instructions. The quality of total RNA was measured by NanoDrop ND-2000 spectrophotometer (Thermo Scientific, Waltham, MA, United States). Total RNA from three paired samples were amplified and transcribed into fluorescent cDNA, and then the fluorescent labeled samples were hybridized to the Agilent LncRNA-mRNA Human Gene Expression Microarray V4.0 (Capital Bio Corp, Beijing, China) which contains 25069 human mRNA according to the manufacturer's recommendations. The microarray was scanned by an Agilent Microarray Scanner. Image processing was conducted using Agilent Feature Extraction software and raw microarray signals normalized using Agilent Gene-Spring software. The normalized mRNA expression profiles data output was received in Excel spreadsheets. The two group of samples data were analyzed by t-test to get the P-values. FC values representing the differently expressed mRNAs between SGC7901/DDP and their parental cells. Cluster 3.0 software was performed to show differential expression patterns of mRNAs.
Bioinformatics analysis
Bioinformatics analysis were generated using KOBAS software and STRING 9.1 software. KOBAS software was used to analyze Ontology, Disease and pathways of the dysregulated mRNAs. KOBAS associated with 1 ontology database (Gene Ontology), 5 disease databases (OMIM, KEGG DISEASE, PID Reactome, FunDO, GAD, NHGRI) and 7 pathway databases (KEGG PATHWAY, PID Curated, PID BioCarta, BioCyc, eactome, Panther). The entire analysis process includes two steps: first, bring the input gene ID map to the gene in the databases, and then annotate pathways, disease and function of these genes involved in. Second step, compare the first step results with background (usually the entire genome of the gene, or the entire probe on the chip), and unearth statistically significant enrichment pathways, disease or function. Fisher's exact test and χ 2 test were used as statistical tests and the FDR was performed to correct the P-value [22] . Additionally, we used STRING 9.1 software to decipher the protein-protein interaction (PPI) network of the differentially expressed proteins. The PPI network may help in understanding the molecular mechanism of cisplatin resistance. All mRNA microarray data were given by Capital Bio Corp.
Quantitative real-time PCR validation of microarray results
To validate the reliability of microarray analysis, we performed quantitative real-time PCR (qRT-PCR). The reverse transcription production cDNA was synthesized using oligo-dT primers and Superscript II reverse transcriptase. PCR 
RESULTS
Sensitivity of SGC7901/DDP and SGC7901 cells to DDP
To determine the chemotherapy sensitivity of SGC7901/DDP and SGC7901 cell line to cisplatin, varying concentrations of cisplatin were added into the 96-well plates and incubated for 48 h. From these data, half maximal inhibitory concentration (IC50) cisplatin dose was calculated. IC50 cisplatin doses for SGC7901/DDP and SGC7901 (after 48 h in DDPcontaining media) were 43.47 ± 0.21 μmol/L and 1.24 ± 0.02 μmol/L, respectively, and the resistance index for SGC7901/DDP cell lines was 35.12, confirming that these cells are refractory to cisplatin. Cell viability was checked by MTT assay (Figure 1 ). (Figure 3 ), indicating the dependability of our microarray platform.
Statistical analysis
To depict comprehensively the properties of the differentially expressed mRNA in SGC7901/DDP cells, GO annotation and enrichment analysis was performed to evaluate which cellular components, molecular functions and biological processes may be are affected by this dysregulation. The GO enrichment analysis showed that the differentially expressed genes were involved in a variety of functions, including locomotion, chemotaxis, cell adhesion, regulation of cell migration, extracellular matrix disassembly, response to xenobiotic chemotaxis, localization of cell adhesion and blood vessel morphogenesis ( Figure 4A ). Additionally, 59 human diseases were significant enriched (P < 0.05) in five human disease databases
Expression profile of mRNAs in SGC7901/DDP cells
To show mRNA expression profile in cisplatin-resistant SGC7901/DDP cells, we used a stringency cutoff to identify significantly differently mRNAs (P < 0.05, FC ≥ 2) and two-dimensional hierarchical clustering 3.0 to represent expression profiles between samples ( Figure 2 ). The results indicated that 1308 mRNAs were significantly differentially expressed in SGC7901/ DDP cells compared with SGC7901 cells. Among these transcripts, 578 mRNAs were upregulated, and 730 mRNAs were downregulated. GC: Gastric cancer.
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Cell viability (KEGG DISEASE, FunDO, GAD, NHGRI GWAS Catalog and OMIM) ( Figure 4B , Table 2 ). Furthermore, it is worth noting that in KEGG disease database, gastric cancer is the most highly enriched disease, and the input genes include DCC, CD44, CDH1, VEGFC, EGF, TGFA.
To determine which pathway might be involved in drug resistance formation, KEGG pathway analysis was used to authenticate pathways and understand biological functions of significantly differentially expressed genes. The result indicated that the differentially expressed mRNAs were enriched for 233 pathways, including the Rap1 signaling pathway, PI3K-Akt signaling pathway, ECM-receptor interaction, TNF signaling pathway, and pathways in cancer, among others ( Figure 5 , Table 3 ). Cluster 3.0 software were performed the heat-map.This finding identified many candidate pathways and input genes that may play an important role in resistance mechanism.
Interaction network analysis
The STRING 9.1 software (Search Tool for the Retrieval of Interacting Genes) was used to perceive functional relations and generate networks of differential expression of proteins ( Figure 6 ). For all of the 1002 differentially expressed proteins, we extracted a network containing 443 upregulated and 559 downregulated proteins which functionally associated with each other. We found that interacting proteins which participate in angiogenesis, toll-like receptor signaling pathway and cell adhesion had a high level of co-expression.
DISCUSSION
Cisplatin is widely used against a variety of solid neoplasms, including testicular, ovarian, colorectal, bladder, head and neck cancers and gastric cancer [23] . However, the repeated clinical expose to cisplatin often results in the tumor cells evading the apoptosis program initiated by cisplatin. Therefore, there is a need to explore the molecular mechanisms of cisplatin resistance, in order to overcome drug resistance in tumor therapy. Recently, several studies have indicated that many proteins are involved in the recognition of Pt-DNA adducts and cisplatin-induced apoptosis program [24, 25] . In this study, we used microarray, GO, KEGG pathway and protein-protein interaction (PPI) analysis to explore the roles of differentially expressed mRNAs in cisplatin resistance and to support other studies.
Many genes which shown differentially expression in the microarray analysis have been demonstrated to be associated with cisplatin resistance in human cancer A B squamous cell carcinoma (SCC) and Hela cells [26] .
Research shows that VEGFC, which is upregulated in our data (P value = 0.00013 FC = 2.93), enhanced cell invasion and cisplatin resistance in gastric cancer [27] . In non-small cell lung cancer, loss of IGFBP-3 expression may activate the PI3K/AKT pathway and induce resistance to cisplatin [28] . In support of this association, our results showed that this mRNA is downregulated (P = 0.00007, FC = 2.93) in SGC7901/DDP cells.
GO enrichment analysis exhibits many functions which the differently expressed mRNAs are involved in, including locomotion, chemotaxis, cell adhesion, ErbB signaling pathway and input genes; E: Jak-STAT signaling pathway and input genes; F: NF-kappa B signaling pathway and input genes; G: HIF-1 signaling pathway and input genes; H: MicroRNAs in cancer and input genes. Each row represents an mRNA, and each column represents a sample. The intensity of the color indicates the relative levels of mRNAs. Red: Higher expression levels; green: Lower expression levels. The name of the input mRNAs which significantly altered (P < 0.05, FC ≥ 2) is present at the right of the figure. been confirmed to be involved in cisplatin resistance in different experiments described previously. For example, the inhibition of PI3K-Akt signaling pathway may increase the sensitivity of gastric cancer cells to cisplatin chemotherapy [29] . Another study found that Janus kinase 2 (JAK2) signal transducer and activator of transcription 3 (STAT3) signaling pathways were activated by overexpressed AKT in cisplatin resistant human gastric cancer cells [30] . A study revealed that the canonical NF-κ B signaling pathway was involved in APRIL-mediated cisplatin resistance in gastric cancer [31] . Our data are consistent with these previous CELF4, TRPS1, TWIST1, PQLC2L, MAL2, PSD3, RCAN2, SUPT3H,  TGFA, TMEM131L, HIVEP3, CSMD1, ROBO2, CCDC54, PRNP, APOC1,  HRK, GPC5, AR, FN1, ABCA13, F2RL2, KLF6, IGF2BP2, LEPREL1, GNG4,  SNAP25, MCTP2, FAM49A, ANKRD50, CACNA2D1, PLXNA2, ELOVL6,  RUNX2, SCN8A, ATXN1, ID2, [26, 32, 33] . Moreover, hub proteins and their partners may have similar biological functions. Since downregulation of EGF has been shown to substantially overcome resistance to cisplatin in ovarian cancer [34] , we predict that the proteins EDN1 and DCN, whose hub protein is EGF, may contribute to cisplatin resistance in a similar fashion. We also found that ZEB2, which over-expressed in SGC7901/DDP compared with SGC7901 has a similar expression profile to TWIST1, suggesting that ZEB2 may play an important role in cisplatin resistance by regulating the expression of TWIST1. Nevertheless, more evidence and research is needed.
In conclusion, our study identified mRNAs differentially expressed between gastric cancer cell lines SGC7901/DDP and SGC7901. These results provide a global view of the function of the differentially expressed mRNAs. Several molecular and pathway abnormalities detected in our study have previously been reported to be associated with drug resistance in gastric cancer. The dysregulated mRNAs identified participate in cisplatin resistance through diverse mechanisms, and further investigation is required to confirm the role in drug resistance of these transcripts, pathways and the interaction networks of the proteins they code for.
COMMENTS
Background
Cisplatin-contained chemotherapy is one of the most frequently used for advanced gastric cancer; however, this chemotherapeutic agent is often limited due to drug resistance and result unsatisfactory prognosis. Research increasingly suggests that abnormal expression of biological pathway and proteins associated with cisplatin resistance. This demonstrated that more bioinformatics study is needed to predict targets for gastric cancer with cisplatin.
Research frontiers
Bioinformatics analysis demonstrated that some mRNAs which related to the biological behavior abnormal expression in SGC7901/DDP cells. These mRNAs have already been shown to play important roles in the process of cisplatin resistance of various cancers, including gastric cancer.
Innovations and breakthroughs
The authors performed bioinformatics analysis of mRNA expression profile in SGC7901/DDP cells compared with SGC7901 cells, and found that many mRNAs and pathways in SGC7901/DDP cells expressed abnormally, these may participate in and predict cisplatin resistance in gastric cancer.
Applications
These results suggest that targeting the differently expression mRNA may provide more selective approaches to reverse cisplatin resistance of therapeutic targets.
Terminology
The definition of cisplatin resistance: in the clinic, if a patient who have disease recurrence within the first months after the recent cisplatin dose, the patient is considered cisplatin resistance; in cells, generally, resistance index > 20 exhibited high resistance, resistance index 5-15 is moderate resistance, resistance index < 5 represent low or no resistance. Correct P: Using Benjamini Hochberg FDR method for correction of p values. Fold change (FC): gene expression in SGC7901 / DDP cells compared with SGC7901 cells.
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The paper is a good study on mRNAs expression profile in SGC7901/DDP cells. The investigators shown that many mRNAs was abnormal expressed in SGC7901/DDP cells and these mRNAs enriched in many biological process which have already been shown to play important roles in the process of cisplatin resistance in human cancer. 
